Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
Standard
Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). / Seidel, C; Busch, J; Weikert, S; Steffens, S; Bokemeyer, C; Grünwald, V.
in: BRIT J CANCER, Jahrgang 109, Nr. 12, 10.12.2013, S. 2998-3004.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
AU - Seidel, C
AU - Busch, J
AU - Weikert, S
AU - Steffens, S
AU - Bokemeyer, C
AU - Grünwald, V
PY - 2013/12/10
Y1 - 2013/12/10
N2 - BACKGROUND: The aim of our analysis is to further characterise the prognostic relevance of early tumour shrinkage (TS) during VEGF-targeted therapy in mRCC, in order to explore whether this could define a group of patients with long-term survivorship.METHODS: A hundred patients were stratified into five subgroups according to their change of tumour size with first treatment evaluation: -100% to -60%; -59% to -30% and -29% to 0% TS or gain of tumour size from 1% to 19% and ≤20% or occurrence of new lesions (i.e., progressive disease).RESULTS: The median PFS and OS were 10.4 months and 28.2 months, respectively. The median OS stratified according to the subgroups as described above was 77.4, 33.5, 26.9, 30.0 and 14.3 months, respectively. Multivariate analysis revealed early TS as a prognostic marker (P=0.021; HR 1.624).CONCLUSION: The extent of TS defines a small proportion of patients with an excellent prognosis. Larger studies are warranted to define the relationship of long-term survivorship and extent of TS with targeted therapies.
AB - BACKGROUND: The aim of our analysis is to further characterise the prognostic relevance of early tumour shrinkage (TS) during VEGF-targeted therapy in mRCC, in order to explore whether this could define a group of patients with long-term survivorship.METHODS: A hundred patients were stratified into five subgroups according to their change of tumour size with first treatment evaluation: -100% to -60%; -59% to -30% and -29% to 0% TS or gain of tumour size from 1% to 19% and ≤20% or occurrence of new lesions (i.e., progressive disease).RESULTS: The median PFS and OS were 10.4 months and 28.2 months, respectively. The median OS stratified according to the subgroups as described above was 77.4, 33.5, 26.9, 30.0 and 14.3 months, respectively. Multivariate analysis revealed early TS as a prognostic marker (P=0.021; HR 1.624).CONCLUSION: The extent of TS defines a small proportion of patients with an excellent prognosis. Larger studies are warranted to define the relationship of long-term survivorship and extent of TS with targeted therapies.
KW - Angiogenesis Inhibitors
KW - Antineoplastic Agents
KW - Carcinoma, Renal Cell
KW - Disease-Free Survival
KW - Female
KW - Humans
KW - Kidney Neoplasms
KW - Male
KW - Middle Aged
KW - Molecular Targeted Therapy
KW - Neoplasm Metastasis
KW - Prognosis
KW - Protein Kinase Inhibitors
KW - Survival Analysis
KW - Treatment Outcome
KW - Vascular Endothelial Growth Factor A
U2 - 10.1038/bjc.2013.662
DO - 10.1038/bjc.2013.662
M3 - SCORING: Journal article
C2 - 24169357
VL - 109
SP - 2998
EP - 3004
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 12
ER -